A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

EverLift Submucosal Lifting Agent in a 10mL Syringe Receives FDA Clearance

October 23, 2020

EverLift Submucosal Lifting Agent in a 10mL syringe, a new device for the lift of polyps, adenomas, early-stage cancers, and other gastrointestinal lesions prior to excision with a snare or other appropriate endoscopic devices, has received FDA clearance. The news was announced today by GI Supply.

EverLift Submucosal Lifting Agent is the only pre-filled Submucosal Lifting Agent in the market available in two presentations, 5mL and 10mL, providing physicians the flexibility to use only what they need and potentially reducing costs to hospitals and ambulatory surgery centers. Also, the pre-filled syringe eliminates the time and expense associated with mixing and preparing the agent.

The new EverLift device provides margin delineation of the lesions with a darker blue color than that offered by other manufacturers1. The darker color is intended to enable safe and complete polyp resections.

“Lifting agents aid in safer resections for patients.  EverLift provides a pliable yet reliable cushion for resection and darker blue hues. The single serve dosing helps reduce waste for everyday polypectomies.” – Dr. Gary “Taavi” Reiss Assistant Professor of Clinical Medicine LSU Health and Director of Interventional GI Metropolitan Gastroenterology Associates.

EverLift’s formulation is cellulose-based, making it hypertonic. This results in a lifting agent that is specially formulated with water-retaining properties, which causes a slower rate of absorption because of osmotic resistance. With an absorption rate slower than other currently available agents2, EverLift provides gastroenterologists with a long lift during their resection procedures.

“The launch of EverLift 10mL completes our offering as now we have two separate presentations of lifting agents in a 5mL and 10mL syringe, to give physicians more flexibility. We are committed to continuing to invest in innovation and this launch is another proof of our continuous investments,” said GI Supply CFO and Interim CEO Kristi Dahlke.

More here.


  1. Survey conducted at DDW, 2019
  2. Based on ex-vivo bench top studies and not in clinical use.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy